David J. Wright
Pfizer
7 Papers
6 Citations
David J. Wright is an academic researcher from Pfizer. The author has contributed to research in topics: Selective estrogen receptor modulator & Bazedoxifene. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals
TL;DR: A case-by-case approach is needed for DART and general toxicity evaluation, which requires consideration of specific product attributes including biochemical and biophysical characteristics, pharmacological activity, and intended clinical indication.
83
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia
TL;DR: The randomized phase 3 Study Of Inotuzumab Ozogamicin Versus Investigator's Choice of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia trial showed that InO was superior to standard of care regimens with a significantly improved complete remission (CR) rate in patients with relapsed/refractory disease.
52
Carcinogenicity and hormone studies with the tissue-selective estrogen receptor modulator bazadoxifene†
David J. Wright,J. Nicole Earnhardt,Richard Perry,Steven Bailey,Barry S. Komm,Daniel R. Minck,Mark A. Cukierski +6 more
TL;DR: Hormonal changes suggest that BZA inhibited both the positive and negative feedback effects of estrogen on gonadotropins and the resulting increase in LH caused formation and persistence of ovarian cysts, which eventually transformed into benign ovarian granulosa cell tumors in the rat carcinogenicity study.
4
Reproductive performance and early postnatal development in interleukin (IL)-13-deficient mice.
TL;DR: IL-13 deficiency had no observed effect on reproductive performance or morphological and behavioral development in mice, and had no impact on any postnatal parameters assessed including reflex, sexual maturation, learning, and memory.
3
Renal tumors in male rats following long-term administration of bazedoxifene, a tissue-selective estrogen receptor modulator.
Rick Perry,Carol A. Thompson,J. Nicole Earnhardt,David J. Wright,Steven Bailey,Barry S. Komm,Mark A. Cukierski +6 more
TL;DR: Findings are consistent with a non-genotoxic mechanism, unique to male rats, that involves test article–induced corticomedullary mineralization, renal tubular injury, and exacerbation of naturally occurring chronic progressive nephropathy in aged male rats that led to a sequela of proliferative changes and tumor formation.
2